Market revenue in 2023 | USD 89.2 million |
Market revenue in 2030 | USD 202.4 million |
Growth rate | 12.4% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.09% in 2023. Horizon Databook has segmented the UK head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
With the increasing prevalence of head & neck cancer and the growing need for therapeutics, regional players are engaged in developing effective & economical treatment therapeutics, fueling market growth in the country.
The presence of sophisticated healthcare infrastructure, collaborations between key market players, and increasing R&D efforts are anticipated to contribute to market growth in the UK. In addition, the high disease burden and significant government interventions in spreading awareness regarding various viral diseases are driving the market.
Moreover, the presence of an established healthcare system, high disposable income, and rise in awareness about early diagnosis of diseases are expected to drive market growth. According to an article published in the British Dental Journal in November 2022, there are an estimated 12,200 new cases of head and neck cancer each year in the UK.
Horizon Databook provides a detailed overview of country-level data and insights on the UK head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into UK head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account